JP2021516682A - 破傷風神経毒素に結合する単一ドメイン抗体 - Google Patents

破傷風神経毒素に結合する単一ドメイン抗体 Download PDF

Info

Publication number
JP2021516682A
JP2021516682A JP2020545344A JP2020545344A JP2021516682A JP 2021516682 A JP2021516682 A JP 2021516682A JP 2020545344 A JP2020545344 A JP 2020545344A JP 2020545344 A JP2020545344 A JP 2020545344A JP 2021516682 A JP2021516682 A JP 2021516682A
Authority
JP
Japan
Prior art keywords
sda
binding
tent
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545344A
Other languages
English (en)
Japanese (ja)
Inventor
スミット， アブラハム ヨハネス デ
スミット， アブラハム ヨハネス デ
マイケル マリー ハームセン，
マイケル マリー ハームセン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smivet BV
Original Assignee
Smivet BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smivet BV filed Critical Smivet BV
Publication of JP2021516682A publication Critical patent/JP2021516682A/ja
Priority to JP2023191811A priority Critical patent/JP2024023268A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020545344A 2018-03-13 2019-03-13 破傷風神経毒素に結合する単一ドメイン抗体 Pending JP2021516682A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191811A JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161521 2018-03-13
EP18161521.2 2018-03-13
PCT/EP2019/056299 WO2019175250A1 (en) 2018-03-13 2019-03-13 Single domain antibodies binding to tetanus neurotoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191811A Division JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Publications (1)

Publication Number Publication Date
JP2021516682A true JP2021516682A (ja) 2021-07-08

Family

ID=61691657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545344A Pending JP2021516682A (ja) 2018-03-13 2019-03-13 破傷風神経毒素に結合する単一ドメイン抗体
JP2023191811A Pending JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191811A Pending JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Country Status (10)

Country Link
US (2) US12054540B2 (https=)
EP (1) EP3765495A1 (https=)
JP (2) JP2021516682A (https=)
CN (2) CN117964751A (https=)
AU (2) AU2019233603B2 (https=)
BR (1) BR112020018563A2 (https=)
MA (1) MA51996A (https=)
MX (2) MX2020009507A (https=)
WO (1) WO2019175250A1 (https=)
ZA (1) ZA202403355B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4352521A4 (en) * 2021-06-07 2025-04-02 Martino, Michael, L. DIAGNOSIS AND TREATMENT BASED ON RAPID RECOGNITION
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503918A (ja) * 1995-04-25 1999-04-06 フリエ・ユニベルシテイト・ブリユツセル 免疫グロブリンの可変断片−治療又は獣医学上の目的のための使用
JP2003503059A (ja) * 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス， テクノロジー アンド メディシン 破傷風毒素ポリペプチド
JP2009524641A (ja) * 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
JP2011504740A (ja) * 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
JP2012183077A (ja) * 2005-07-08 2012-09-27 Biogen Idec Ma Inc 抗αＶβ６抗体およびその使用
JP2013536191A (ja) * 2010-08-12 2013-09-19 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドβペプチド抗体及びその使用
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
JP2016528884A (ja) * 2013-06-28 2016-09-23 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JP2017538414A (ja) * 2014-12-09 2017-12-28 ニューヨーク・ユニバーシティ クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
AUPS022802A0 (en) * 2002-01-31 2002-02-21 Macfarlane Burnet Institute For Medical Research And Public Health Limited, The Anti-viral compounds
AU2004245429A1 (en) 2003-06-10 2004-12-16 Farallone Holding Bv Binding peptides: methods for their generation and use
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
BR112014011137A2 (pt) * 2011-11-09 2018-06-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento
US9670275B2 (en) * 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN107428840A (zh) * 2015-03-25 2017-12-01 弗劳恩霍夫应用研究促进协会 抗cd89细胞毒素的复合物

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503918A (ja) * 1995-04-25 1999-04-06 フリエ・ユニベルシテイト・ブリユツセル 免疫グロブリンの可変断片−治療又は獣医学上の目的のための使用
JP2003503059A (ja) * 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス， テクノロジー アンド メディシン 破傷風毒素ポリペプチド
JP2012183077A (ja) * 2005-07-08 2012-09-27 Biogen Idec Ma Inc 抗αＶβ６抗体およびその使用
JP2009524641A (ja) * 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
JP2011504740A (ja) * 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
JP2013536191A (ja) * 2010-08-12 2013-09-19 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドβペプチド抗体及びその使用
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
JP2016528884A (ja) * 2013-06-28 2016-09-23 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
JP2017538414A (ja) * 2014-12-09 2017-12-28 ニューヨーク・ユニバーシティ クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS, vol. 414, JPN6023002788, 1997, pages 521 - 526, ISSN: 0005104286 *
MABS, vol. 7, no. 5, JPN6023002787, 2015, pages 820 - 828, ISSN: 0005104287 *

Also Published As

Publication number Publication date
CN112135840A (zh) 2020-12-25
BR112020018563A2 (pt) 2020-12-29
JP2024023268A (ja) 2024-02-21
US12054540B2 (en) 2024-08-06
MX2025004782A (es) 2025-05-02
EP3765495A1 (en) 2021-01-20
WO2019175250A1 (en) 2019-09-19
AU2019233603A1 (en) 2020-09-17
US20220275066A1 (en) 2022-09-01
CN117964751A (zh) 2024-05-03
AU2025234234A1 (en) 2025-10-09
MX2020009507A (es) 2020-10-22
CN112135840B (zh) 2024-01-23
US20240376185A1 (en) 2024-11-14
MA51996A (fr) 2021-01-20
ZA202403355B (en) 2024-12-18
AU2019233603B2 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
JP7277370B2 (ja) 獣医用抗ｉｌ－３１抗体
JP7241731B2 (ja) 血清アルブミン結合剤
US20240376185A1 (en) Tetanus prophylaxis
EP2670779B1 (en) Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
US20210347868A1 (en) Anti-synuclein antibodies
US20240132624A1 (en) Polypeptides binding to a specific epitope of the neonatal fc receptor
Meng et al. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein
Rossotti et al. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain
CN101386648B (zh) 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
CA3198333A1 (en) Antibody compositions for treatment of corona virus infection
WO2025061919A1 (en) Bi- and multivalent albumin binders
US20180105584A1 (en) Antibody directed against immunoglobulin-binding proteins of s. aureus
US11505598B2 (en) Antibodies to botulinum neurotoxins
WO2023201192A2 (en) Antibodies to botulinum neurotoxins
AU2024347237A1 (en) Bi- and multivalent albumin binders
WO2025219586A1 (en) Vhh antibodies which bind to canine il-31
WO2025219585A1 (en) Vhh antibodies which bind to canine albumin
HK1152339A (en) Composition for neutralizing botulinus toxin type-a, and human anti-botulinus toxin type-a antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201019

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260424